Home ›
Data Desk › Lyell Immunopharma Inc. puts an S-3 shelf registration on file
MarginsX Data Desk · Offerings · Dilution · Cell and gene therapy · Private placement (PIPE) · Oncology
Lyell Immunopharma Inc. puts an S-3 shelf registration on file
On Nov 13, 2026, Lyell Immunopharma Inc. (LYEL) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)
By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 13, 2026.
Cash and dilution
It reported cash of $92.1M as of Sep 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
At its recent quarterly burn rate that cash lasts about 7.9 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
Its share count rose 15.9% over the past year. (Company health, computed by us from SEC filings and XBRL, Oct 30, 2026)
The stock
The Nasdaq screener puts its market value at $351.6M. (Nasdaq stock screener, Nov 13, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/LYEL)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.
Facts behind this article
| Fact | Value | Source | As of |
|---|
| Name | Lyell Immunopharma Inc. | Source | 2026-11-13 |
| Form | S-3 | Source | 2026-11-13 |
| Filed | Nov 13, 2026 | Source | 2026-11-13 |
| Who | Lyell Immunopharma Inc. (LYEL) | Source | 2026-11-13 |
| Symbol | LYEL | Source | 2026-11-13 |
| Cash | 92,053,000 USD | Source | 2026-09-30 |
| Cash date | Sep 30, 2026 | Source | 2026-09-30 |
| Runway | 7.9 months | Source | 2026-09-30 |
| Dilution 1y | 15.9 % | Source | 2026-10-30 |
| Cap | 351,573,580 USD | Source | 2026-11-13 |
Sources
Automated from SEC filings and market data. No AI. For information only. Not investment advice.
Discuss in MarginsX More from the Data Desk
More on MarginsX
Companies in this article
Topics
Related Data Desk stories
Every Data Desk article: /desk · RSS